• A prospective, screening strategy in adults receiving first allogeneic HCT at 3 centers showed a 21.8% incidence of severe TA-TMA.

  • Patients with severe TA-TMA have significantly higher nonrelapse and overall mortality than patients with nonsevere and no TA-TMA.

Abstract

No prospective study has evaluated the incidence of transplant-associated thrombotic microangiopathy (TA-TMA) in adult allogeneic hematopoietic cell transplant (HCT) recipients. The MIDAS (microangiopathy, endothelial damage in adults undergoing stem cell transplantation) Consortium conducted, to our knowledge, the first multicenter study to prospectively screen for TA-TMA. Longitudinal blood samples and detailed clinical data were collected weekly through day +100 and at months 5, 6, 9, and 12 from first allogeneic HCT recipients at 3 sites (The Ohio State University, Moffitt Cancer Center, and Roswell Park Comprehensive Cancer Center). Adjudication of TA-TMA diagnosis was reviewed in real time by 3 blinded independent reviewers. Incidence of TA-TMA was scored using 6 published criteria, as well as the center-reported diagnosis and MIDAS adjudication categorized as none, nonsevere, or severe TA-TMA. Incidence of severe TA-TMA by day +100 was similar across the 3 centers at 21.8%, with a median onset of 14.5 days in 239 patients. Incidence of nonrelapse mortality was 42% in severe compared with 8.4% in nonsevere and 5.8% in no-TMA groups (P < .001). Rise in serum creatinine as early as day +7 and occurrence of hypertension by day +14 after HCT were early indicators of severe TA-TMA. Our prospective study of systematic screening for TA-TMA identifies a higher incidence of a clinically impactful phenotype of TA-TMA than previously reported in adult HCT recipients. Our natural history study provides an essential foundation for urgently needed studies of TA-TMA prophylaxis and treatment in adults and suggests clinical value in our inexpensive screening strategy.

1.
Dvorak
CC
.
TA-TMA: state of the art for diagnosis and treatment
.
Blood Adv
.
2020
;
4
(
1
):
217
.
2.
Li
A
,
Wu
Q
,
Davis
C
, et al
.
Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal
.
Biol Blood Marrow Transpl
.
2019
;
25
(
3
):
570
-
576
.
3.
Gavriilaki
E
,
Sakellari
I
,
Anagnostopoulos
A
,
Brodsky
RA
.
Transplant-associated thrombotic microangiopathy: opening Pandora’s box
.
Bone Marrow Transpl
.
2017
;
52
(
10
):
1355
-
1360
.
4.
Van Benschoten
V
,
Roy
C
,
Gupta
R
,
Ouellette
L
,
Hingorani
S
,
Li
A
.
Incidence and risk factors of transplantation-associated thrombotic microangiopathy: a systematic review and meta-analysis
.
Transpl Cell Ther
.
2022
;
28
(
5
):
266.e1
-
266.e8
.
5.
Epperla
N
,
Li
A
,
Logan
B
, et al
.
Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy
.
Br J Haematol
.
2020
;
189
(
6
):
1171
-
1181
.
6.
Li
A
,
Gupta
R
,
Amos
CI
, et al
.
Thrombotic microangiopathy increases the risk of chronic kidney disease but not overall mortality in long-term transplant survivors
.
Transpl Cell Ther
.
2021
;
27
(
10
):
864.e1
-
864.e5
.
7.
Schoettler
ML
,
Carreras
E
,
Cho
B
, et al
.
Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research
.
Transpl Cell Ther
.
2023
;
29
(
3
):
151
-
163
.
8.
Jodele
S
,
Davies
SM
,
Lane
A
, et al
.
Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
.
Blood
.
2014
;
124
(
4
):
645
-
653
.
9.
Dandoy
CE
,
Rotz
S
,
Alonso
PB
, et al
.
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant
.
Blood Adv
.
2021
;
5
(
1
):
1
-
11
.
10.
Jodele
S
,
Laskin
BL
,
Dandoy
CE
, et al
.
A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury
.
Blood Rev
.
2015
;
29
(
3
):
191
-
204
.
11.
Jodele
S
,
Dandoy
CE
,
Lane
A
, et al
.
Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab
.
Blood
.
2020
;
135
(
13
):
1049
-
1057
.
12.
Cho
BS
,
Yahng
SA
,
Lee
SE
, et al
.
Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation
.
Transplantation
.
2010
;
90
(
8
):
918
-
926
.
13.
Ho
VT
,
Cutler
C
,
Carter
S
, et al
.
Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation
.
Biol Blood Marrow Transpl
.
2005
;
11
(
8
):
571
-
575
.
14.
Ruutu
T
,
Barosi
G
,
Benjamin
RJ
, et al
.
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group
.
Haematologica
.
2007
;
92
(
1
):
95
-
100
.
15.
Li
A
,
Wu
Q
,
Davis
C
, et al
.
Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal
.
Biol Blood Marrow Transpl
.
2019
;
25
(
3
):
570
-
576
.
16.
Gavriilaki
E
,
Sakellari
I
,
Batsis
I
, et al
.
Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation
.
Clin Transpl
.
2018
;
32
(
9
):
e13371
.
17.
Schoettler
M
,
Lehmann
LE
,
Margossian
S
, et al
.
Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort
.
Blood Adv
.
2020
;
4
(
11
):
2536
-
2547
.
18.
Li
A
,
Sartain
SE
.
Transplant-associated TMA: the conundrum of diagnosis and treatment
.
Hematology
.
2024
;
2024
(
1
):
206
-
213
.
19.
Java
A
.
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy
.
Hematology
.
2024
;
2024
(
1
):
200
-
205
.
20.
Nester
CM
,
Feldman
DL
,
Burwick
R
, et al
.
An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
.
Kidney Int
.
2024
;
106
(
3
):
326
-
336
.
21.
Saha
BK
,
Saha
A
,
Chong
W
,
Beegle
S
.
A Fatal case of thrombotic microangiopathy without schistocytosis and absent biochemical markers of hemolysis
.
Am J Med Sci
.
2020
;
359
(
5
):
296
-
302
.
22.
Murphree
CR
,
Nguyen
NN
,
Shatzel
JJ
, et al
.
Biopsy-proven thrombotic microangiopathy without schistocytosis on peripheral blood smear: a cautionary tale
.
Am J Hematol
.
2019
;
94
(
9
):
E234
-
E237
.
23.
Schoettler
ML
,
Williams
KM
.
Application of the consensus definition of transplant associated thrombotic microangiopathy (TA-TMA) requires a more expansive lens to accurately diagnose and risk stratify patients—beware reliance on schistocytes alone
.
Transpl Cell Ther
.
2024
;
30
(
8
):
818
-
820
.
24.
Moiseev
IS
,
Tsvetkova
T
,
Aljurf
M
, et al
.
Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT
.
Bone Marrow Transpl
.
2019
;
54
(
7
):
1022
-
1028
.
25.
Zini
G
,
d’Onofrio
G
,
Erber
WN
, et al
.
2021 update of the 2012 ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes: impact and revisions
.
Int J Lab Hematol
.
2021
;
43
(
6
):
1264
-
1271
.
26.
Miyata
M
,
Matsuki
E
,
Ichikawa
K
, et al
.
Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation
.
Blood Adv
.
2023
;
7
(
22
):
6936
-
6948
.
27.
Mariotti
J
,
Penack
O
,
Castagna
L
.
Acute graft-versus-host-disease other than typical targets: between myths and facts
.
Transpl Cell Ther
.
2021
;
27
(
2
):
115
-
124
.
28.
Girsberger
M
,
Halter
JP
,
Hopfer
H
,
Dickenmann
M
,
Menter
T
.
Kidney pathology after hematologic cell transplantation—a single-center observation study of indication biopsies and autopsies
.
Biol Blood Marrow Transpl
.
2018
;
24
(
3
):
571
-
580
.
29.
Changsirikulchai
S
,
Myerson
D
,
Guthrie
KA
,
McDonald
GB
,
Alpers
CE
,
Hingorani
SR
.
Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis
.
Clin J Am Soc Nephrol
.
2009
;
4
(
2
):
345
-
353
.
30.
Hingorani
S
,
Guthrie
KA
,
Schoch
G
,
Weiss
NS
,
McDonald
GB
.
Chronic kidney disease in long-term survivors of hematopoietic cell transplant
.
Bone Marrow Transpl
.
2007
;
39
(
4
):
223
-
229
.
31.
Penack
O
,
Luft
T
,
Peczynski
C
, et al
.
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study
.
J Immunother Cancer
.
2024
;
12
(
1
):
e007635
.
32.
Luft
T
,
Benner
A
,
Terzer
T
, et al
.
EASIX and mortality after allogeneic stem cell transplantation
.
Bone Marrow Transpl
.
2020
;
55
(
3
):
553
-
561
.
33.
Li
A
,
Wu
QV
,
Hilton
T
, et al
.
Soluble C5b-9 as a prognostic biomarker for thrombotic microangiopathy at the onset of graft-versus-host disease [abstract]
.
Blood
.
2019
;
134
(
suppl 1
):
40
.
34.
Luft
T
,
Dreger
P
,
Radujkovic
A
.
Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation
.
Bone Marrow Transpl
.
2021
;
56
(
10
):
2326
-
2335
.
You do not currently have access to this content.
Sign in via your Institution